Ketamine has moved from the margins of psychiatry into mainstream conversation, and for good reason. For people who have struggled with treatment-resistant depression, tried multiple medications without relief, and felt like they were running out of options, ketamine represents real hope. At the same time, a growing number of at-home ketamine services have made it easier than ever to access ketamine-class treatments without stepping into a clinic. That accessibility raises a question we hear often: is at-home ketamine actually safe?
Ketamine, administered correctly in the right setting, can offer real relief for people who haven’t responded to conventional approaches. But the setting matters enormously, and understanding why is the difference between a treatment that helps and one that puts you at risk. Here’s how at-home ketamine services work, what the risks look like without clinical supervision, what in-clinic treatment involves, and why SPRAVATO’s mandatory in-office administration reflects known safety data rather than bureaucratic caution.
At-home ketamine programs became more visible over the past few years, largely because telehealth expansion made it easier for companies to reach patients across state lines. The general model: a patient completes an online intake form and a telehealth consultation with a prescribing provider. If approved, they receive a supply of ketamine in sublingual tablet or lozenge form, mailed to their home. They then self-administer during sessions they conduct on their own, sometimes with optional virtual check-ins.
One thing often gets lost in how these services are marketed: at-home programs don’t use intravenous infusions. They rely on oral or sublingual formulations dissolved under the tongue or swallowed, and that delivery difference has real clinical consequences.
When ketamine is delivered intravenously, it enters the bloodstream directly. Plasma concentrations rise quickly and predictably, and the clinical team can observe and respond to the patient’s experience in real time. Sublingual and lozenge formulations are absorbed through the mucous membranes or the gastrointestinal tract, where bioavailability is lower and more variable. Onset is slower, the peak experience is generally less intense, and the amount of drug that actually reaches the bloodstream can differ from one session to the next depending on how the patient holds it under their tongue, how much they swallow, and individual metabolism.
That variability isn’t a pharmacological footnote. A patient at home may have one session that feels mild and manageable, and another that produces a far more intense dissociative experience than expected, with no clinical staff present to help them through it.
The regulatory picture matters too. These services operate in a gray area. Ketamine itself is an FDA-approved anesthetic, and physicians can legally prescribe it off-label for depression. But the at-home model isn’t equivalent to FDA-cleared depression treatment. SPRAVATO, the esketamine nasal spray approved in 2019 for treatment-resistant depression, must by law be administered in a certified healthcare setting under direct supervision, because the FDA reviewed the safety profile of ketamine-class drugs and concluded that unsupervised use carries real risk. At-home programs aren’t subject to those requirements, so the oversight patients receive varies widely from one service to the next.
Ketamine isn’t a benign supplement. It’s a dissociative anesthetic with physiological effects that call for monitoring, and those effects don’t shrink because a patient is sitting in their living room instead of a clinic.
Physiologically, ketamine reliably raises blood pressure and heart rate. In a clinical setting, vitals are tracked throughout the session and the care team responds if values climb. At home, there’s no monitoring. For patients with undiagnosed or poorly controlled hypertension, that’s a real risk. At higher doses, ketamine can also affect respiratory function, one reason it has long been used as an anesthetic. Sublingual doses run lower than IV infusions, but the risk doesn’t disappear, particularly if a patient takes more than prescribed or reacts unexpectedly.
Nausea is common during sessions and disorienting to handle alone. The dissociative experience itself is the bigger issue. Ketamine produces a state in which a person may feel detached from their body, their surroundings, or their sense of self. In a clinical setting, with a trained clinician offering calm reassurance, that experience is usually manageable and can even support the therapy. Without that support, the same experience can turn frightening. Panic, confusion, and psychological distress during a dissociative episode aren’t rare, and they’re much harder to get through without professional presence.
Then there’s dependency. Ketamine has a known potential for misuse, particularly with frequent use outside a controlled protocol. Clinical programs are structured specifically to prevent this: sessions spaced according to evidence-based protocols, frequency monitored, clinicians watching for rising tolerance. At-home programs, even well-intentioned ones, can’t replicate that oversight. When a patient controls their own supply and dosing schedule, the structure that protects against misuse is largely gone.
None of this means everyone who tries at-home ketamine will have a dangerous experience. But the risks are real, they’re known, and they’re the exact reason supervised clinical administration exists. Convenience doesn’t substitute for safety infrastructure.
In a supervised infusion setting, ketamine is administered intravenously by trained clinical staff while the patient reclines in a calm, comfortable environment. A clinician monitors vitals continuously: blood pressure, heart rate, oxygen saturation. The dose is calculated from the patient’s body weight, medical history, current medications, and therapeutic goals. That precision matters because ketamine’s therapeutic window is relatively narrow. Too little and the treatment doesn’t work; too much and the risks climb.
The clinician’s presence serves two purposes. Practically, if a patient experiences distressing dissociation, elevated blood pressure, or nausea, the team responds immediately. Therapeutically, a patient who feels frightened or overwhelmed mid-session has a grounded, calm presence to orient them. Many clinicians consider the quality of the ketamine experience, including how safe and supported it feels, part of what makes the treatment effective.
Reputable clinics also provide integration support after each session. The period following an infusion, when the brain may be in a heightened state of neuroplasticity, gets used therapeutically rather than left unaddressed: patients process what they experienced, discuss it with a clinician, and connect it to their broader treatment goals. This follow-up component is frequently missing from at-home programs, and its absence is a real gap in care. You can read what a session is like from a patient’s perspective on our ketamine infusion experience page.
The in-clinic model also supports the full course of treatment, not just individual sessions. Clinicians track response over time, adjust protocols as needed, and coordinate with the patient’s other providers. That longitudinal oversight is what turns ketamine from a one-time experience into part of a complete treatment plan.
One of the most important functions of a legitimate ketamine clinic happens before any treatment: determining if the patient is actually a good candidate. This screening is a clinical safeguard, and it’s one area where at-home services vary widely in rigor.
Thorough screening includes a psychiatric evaluation to establish diagnosis and treatment history, a review of current and past medications, a medical history assessment, and contraindication screening. That takes physician-level judgment, not a checklist completed online.
Clear contraindications make ketamine unsafe for some people. A history of psychosis or schizophrenia is among the most serious, because ketamine can worsen psychotic symptoms. Uncontrolled hypertension is another, given the cardiovascular effects. Active substance use disorder requires careful evaluation because of the dependency potential, and certain cardiac conditions and drug interactions, including MAOIs, need physician review. These aren’t edge cases; a fair share of people seeking mental health treatment have one of them, and abbreviated online intakes can miss them.
Ketamine also isn’t for everyone who’s curious about it. It’s most appropriate for treatment-resistant depression and specific mood disorders in patients who haven’t found relief through conventional antidepressants and therapy. It’s not a first-line treatment. Proper candidacy evaluation is how the people who receive ketamine end up being the ones most likely to benefit safely. You can read more about our approach to ketamine therapy for depression and what the process looks like for appropriate candidates.
SPRAVATO is the brand name for esketamine, a nasal spray formulation the FDA approved in 2019 for treatment-resistant depression. It’s chemically related to ketamine but not identical: esketamine is a specific enantiomer of ketamine, one of two mirror-image molecular forms, developed and studied specifically for depression rather than repurposed from anesthesia.
What separates SPRAVATO from at-home ketamine most clearly isn’t the chemistry. It’s the regulatory framework. SPRAVATO falls under the FDA’s Risk Evaluation and Mitigation Strategy, the REMS program. Under REMS, SPRAVATO can only be dispensed through certified healthcare facilities. Patients self-administer the spray under direct supervision at the clinic and must be monitored for at least two hours after each dose before leaving. That isn’t a guideline. It’s a legal requirement tied to the drug’s approval.
REMS exists because the FDA reviewed the clinical data on esketamine and found the risks of dissociation, sedation, and misuse serious enough to require mandatory oversight. Patients have experienced real drops in blood pressure, deep dissociative states, and sedation after SPRAVATO doses. Those are manageable in a supervised setting with trained staff. They aren’t manageable alone at home.
People comparing at-home ketamine to SPRAVATO sometimes assume the in-office requirement is a bureaucratic hurdle. The REMS data says otherwise: the requirement reflects what clinical trials showed about ketamine-class drugs without oversight. At-home products aren’t subject to REMS, so they aren’t held to the same safety standard, even though the underlying risks of the drug class are similar. That’s why we take the position we do on supervised administration. It aligns with what the evidence says about delivering ketamine-class treatment safely.
Ketamine isn’t inherently dangerous. It has been used safely in medical settings for decades, the research on its antidepressant effects in treatment-resistant populations is promising, and we’ve seen it make a real difference for patients who felt they’d run out of options. The drug isn’t the problem; the context it’s used in determines its safety and effectiveness.
If you’re evaluating any ketamine provider, look for four things: physician oversight throughout the process, screening that includes a psychiatric evaluation and contraindication review, monitored sessions with clinical staff present and vitals tracked, and some form of integration support or follow-up care beyond the infusion itself.
We understand the appeal of at-home options, especially for people already exhausted from managing a hard mental health condition. But when the treatment is a dissociative anesthetic with known cardiovascular and psychological effects, convenience shouldn’t come at the cost of the safety infrastructure that makes the treatment work as intended. Don’t let a mailed prescription substitute for the evaluation and oversight that protect you through the process.
At Delray Brain Science, we offer full psychiatric assessments and medically supervised ketamine treatment for patients with treatment-resistant depression and related conditions. We take screening seriously because we take your safety seriously. If you’d like to find out if ketamine treatment fits your situation, reach out to our team to schedule a consultation and we’ll walk through your history and options together.
